Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion ProteinCharles J. Fisher, Ernest Benjamin, Jan M. Agosti et al.|New England Journal of Medicine|1996Cited by 1.3k
Confirmatory interleukin-1 receptor antagonist trial in severe sepsisSteven M. Opal, Michael G. Seneff, H. C. E. Donovan et al.|Critical Care Medicine|1997Cited by 863
Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICURussell R. Miller, Richard B. Brandon, Bert K. Lopansri et al.|American Journal of Respiratory and Critical Care Medicine|2018Cited by 126
Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial*Daniel P. Schuster, John P. Pribble, Michael H. Metzler et al.|Critical Care Medicine|2003Cited by 82
From the bench to the bedside: the future of sepsis research. Executive summary of an American College of Chest Physicians, National Institute of Allergy and Infectious Disease, and National Heart, Lung, and Blood Institute Workshop.R. Phillip Dellinger, Samuel D. Wright, Steven M. Opal et al.|PubMed|1997Cited by 62